A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
M.D. Anderson Cancer Center
Seagen Inc.
Pliant Therapeutics, Inc.
Pfizer
Merck Sharp & Dohme LLC
Blokhin's Russian Cancer Research Center
Teclison Ltd.
Genentech, Inc.
National Cancer Institute (NCI)
Bristol-Myers Squibb
Genmab
Pfizer
Vividion Therapeutics, Inc.
Merck Sharp & Dohme LLC
Erasca, Inc.
Novartis
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Pfizer
Dana-Farber Cancer Institute
PMV Pharmaceuticals, Inc
Sutro Biopharma, Inc.
National Institutes of Health Clinical Center (CC)
IFOM ETS - The AIRC Institute of Molecular Oncology
Neonc Technologies, Inc.
Seagen Inc.
Tizona Therapeutics, Inc
Essen Biotech
Amgen
IDEAYA Biosciences
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
ImmunityBio, Inc.
Eli Lilly and Company
Novartis
University of California, San Francisco
M.D. Anderson Cancer Center
Amgen
Sairopa B.V.
University of Pittsburgh
The Netherlands Cancer Institute
Curacell Holding AB
Memorial Sloan Kettering Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Merck Sharp & Dohme LLC
Twinpig Biolab, Inc.
National Cancer Centre, Singapore
Merck Sharp & Dohme LLC
Sotio Biotech Inc.